Virus-Like Particles of mRNA with Artificial Minimal Coat Proteins: Particle Formation, Stability, and Transfection Efficiency

Nucleic Acid Therapeutics

Volumn 27, Issue 3, 2017, Pages 159-167

  Jekhmane, Shehrazade ^a   De Haas, Rob ^a   Paulino Da Silva Filho, Omar ^b,c   Van Asbeck, Alexander H ^b   Favretto, Marco Emanuele ^b,e   Hernandez Garcia, Armando ^d,f   Brock, Roland ^b   De Vries, Renko ^a  

^a WAGENINGEN UNIVERSITY   (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^c MINISTRY OF EDUCATION OF BRAZIL   (Brazil)

^d Northwestern University   (United States)

^e UNIVERSITY OF CHESTER   (United Kingdom)

^f UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

Author keywords

mRNA delivery; self assembly; Virus like particles

Indexed keywords

COAT PROTEIN; DNA; DOUBLE STRANDED DNA; ENHANCED GREEN FLUORESCENT PROTEIN; MESSENGER RNA; OLIGONUCLEOTIDE; RIBONUCLEASE; CAPSID PROTEIN; FLUORESCENT DYE; GREEN FLUORESCENT PROTEIN; LUCIFERASE; VIRUS LIKE PARTICLE VACCINE;

ARTICLE; ATOMIC FORCE MICROSCOPY; CELL ENCAPSULATION; CELL FUNCTION; CELL SPECIFICITY; CELL VIABILITY; CONFOCAL LASER SCANNING MICROSCOPY; CYTOTOXICITY; ENZYMATIC DEGRADATION; FEMALE; GENETIC CODE; GENETIC TRANSFECTION; HEMOLYSIS; HUMAN; HUMAN CELL; IN VITRO STUDY; PHOTON CORRELATION SPECTROSCOPY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN STABILITY; TARGET CELL; VIRUS LIKE AGENT; CELL SURVIVAL; CHEMISTRY; COLLOID; HEK293 CELL LINE; HELA CELL LINE; METABOLISM; NANOMEDICINE; RNA STABILITY; TRENDS; ULTRASTRUCTURE;

CAPSID PROTEINS; CELL SURVIVAL; COLLOIDS; DNA; FLUORESCENT DYES; GREEN FLUORESCENT PROTEINS; HEK293 CELLS; HELA CELLS; HEMOLYSIS; HUMANS; LUCIFERASES; MICROSCOPY, ATOMIC FORCE; NANOMEDICINE; RNA STABILITY; RNA, MESSENGER; TRANSFECTION; VACCINES, VIRUS-LIKE PARTICLE;

EID: 85020226699     PISSN: 21593337     EISSN: 21593345     Source Type: Journal    
DOI: 10.1089/nat.2016.0660     Document Type: Article

References (20)

1. Kallen KJ and A Theß. (2014). A development that may evolve into a revolution in medicine: mRNA as the basis for novel, nucleotide-based vaccines and drugs. Ther Adv Vaccines 2:10-31.
2. Tavernier G, O Andries, J Demeester, NN Sanders, SC De Smedt and J Rejman. (2011). mRNA as gene therapeutic: how to control protein expression. J Control Release 150: 238-247.
3. Yamamoto A, M Kormann, J Rosenecker and C Rudolph. (2009). Current prospects for mRNA gene delivery. Eur J Pharm Biopharm 71:484-489.
4. Gilboa E and J Vieweg. (2004). Cancer immunotherapy with mRNA-transfected dendritic cells. Immunol Rev 199: 251-263.
5. Jayaraman M, SM Ansell, BL Mui, YK Tam, J Chen, X Du, D Butler, L Eltepu, S Matsuda, et al. (2012). Maximizing the potency of siRNA lipid nanoparticles for hepatic gene silencing in vivo. Angew Chem Int Ed 51:8529-8533.
6. Bertrand N and JC Leroux. (2012). The journey of a drugcarrier in the body: an anatomo-physiological perspective. J Control Release 161:152-163.
7. Hernandez-Garcia A, DJ Kraft, AF Janssen, PH Bomans, NA Sommerdijk, DM Thies-Weesie, ME Favretto, R Brock, FA de Wolf, et al. (2014). Design and self-assembly of simple coat proteins for artificial viruses. Nat Nanotechnol 9:698-702.
8. Schindelin J, I Arganda-Carreras, E Frise, V Kaynig, M Longair, T Pietzsch, S Preibisch, C Rueden, S Saalfeld, et al. (2012). Fiji: an open-source platform for biologicalimage analysis. Nat Methods 9:676-682.
9. Favretto ME, A Krieg, S Schubert, US Schubert and R Brock. (2015). Multifunctional poly(methacrylate) polyplex libraries: a platform for gene delivery inspired by nature. J Control Release 209:1-11.
10. Werten MW, WH Wisselink, TJ Jansen-van den Bosch, EC de Bruin and FA de Wolf. (2001). Secreted production of a custom-designed, highly hydrophilic gelatin in Pichia pastoris. Protein Eng 14:447-454.
11. Crommelin DJ, G Storm, W Jiskoot, R Stenekes, E Mastrobattista and WE Hennink. (2003). Nanotechnological approaches for the delivery of macromolecules. J Control Release 87:81-88.
12. Plank C, W Zauner and E Wagner. (1998). Application of membrane-active peptides for drug and gene delivery across cellular membranes. Adv Drug Deliv Rev 34:21-35.
13. Lia W, F Nicola and FC Szoka Jr. (2004). GALA: a designed synthetic pH-responsive amphipathic peptide with applications in drug and gene delivery. Adv Drug Deliv Rev 56:967-985.
14. Mastrobattista E, MAEM van der Aa, WE Hennink, DJA Crommelin. (2006). Artificial viruses: a nanotechnological approach to gene delivery. Nat Rev Drug Discov 5:115-121.
15. Strohl WR. (2015). Fusion proteins for half-life extension of biologics as a strategy to make biobetters. BioDrugs 29: 215-239.
16. Liu W, MR Dreher, DY Furgeson, KV Peixoto, H Yuan, MR Zalutsky and A Chilkoti. (2006). Tumor accumulation, degradation and pharmacokinetics of elastin-like polypeptides in nude mice. J Control Release 116:170-178.
17. Chilkoti A. (2013). Fusion peptide therapeutic compositions. US Patent 2013/0143802 A1.
18. Schlapschy M, U Binder, C Börger, I Theobald, K Wachinger, S Kisling, D Haller and A Skerra. (2013). PASylation: a biological alternative to PEGylation for extending the plasma half-life of pharmaceutically active proteins. Protein Eng Des Sel 26:489-501.
19. Schellenberger V, C-W Wang, NC Geething, BJ Spink, A Campbell, W To, MD Scholle, Y Yin, Y Yao, et al. (2009). A recombinant polypeptide extends the in vivo half-life of peptides and proteins in a tunable manner. Nat Biotechnol 27:1186-1190.
20. Urry DW, TM Parker, MC Reid and C Gowda. (1991). Biocompatibility of the bioelastic materials, Poly(GVGVP) and its g-irradiation cross-linked matrix: summary of generic biological test results. J Bioact Compat Polym 6:263.